ResApp to Present at TechKnow Invest Roadshow Webinar

Brisbane, Australia, 11 May 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise shareholders and investors that ResApp CEO and Managing Director, Tony Keating, will present at the TechKnow Invest Roadshow webinar to be held at 1:30pm AEST on Tuesday the 12th of May.

The event is free and investors can register online to view the presentation here: https://www.resapphealth.com.au/techknow/

After registering you will receive an email with all login details (a website link or phone dial in details).

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating	Mr Brian Leedman
CEO and Managing Director	Vice President, Corporate Affairs
+61 430 180 659	+61 412 281 780
tony@resapphealth.com.au	brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.